Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

World Cough Pipeline Review 2016 - 18 Companies & 26 Molecules - Research and Markets

Research and Markets
Posted on: 12 Oct 16

Research and Markets has announced the addition of the "Cough - Pipeline Review, H2 2016" report to their offering.

A cough is a common reflex action that aims to clear the throat of mucus or foreign irritants. Dry cough, chronic cough and whooping cough (also known as pertussis) are distinct types of cough. Symptoms include runny or stuffy nose, hoarseness, wheezing and shortness of breath, heartburn or a sour taste in mouth and rarely coughing up blood. The predisposing factors include asthma, chronic obstructive pulmonary disease, cigarette smoking, lung diseases such as bronchiectasis, interstitial lung disease, or tumors, lung infections such as pneumonia or acute bronchitis and allergic rhino sinusitis. Treatment includes cough suppressants, oral expectorants, and topical (externally applied) drugs.

Cough pipeline therapeutics constitutes close to 26 molecules. Out of which approximately 25 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 3, 8, 10, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cough - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Cough Overview
  3. Therapeutics Development
  4. Pipeline Products for Cough - Overview
  5. Pipeline Products for Cough - Comparative Analysis
  6. Cough - Therapeutics under Development by Companies
  7. Cough - Therapeutics under Investigation by Universities/Institutes
  8. Cough Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Cough - Products under Development by Companies
  13. Cough - Products under Investigation by Universities/Institutes
  14. Cough - Companies Involved in Therapeutics Development
  • Afferent Pharmaceuticals, Inc.
  • Alitair Pharmaceuticals, Inc.
  • Alveonix AG
  • AstraZeneca Plc
  • AusBio Ltd
  • Charleston Laboratories, Inc.
  • Conrig Pharma ApS
  • Daewoong Pharmaceutical Co., Ltd.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • GW Pharmaceuticals Plc
  • Hyundai Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • NeRRe Therapeutics Ltd
  • Orbis Biosciences Inc
  • Patara Pharma, Inc.
  • Pila Pharma AB
  • Vernalis Plc

For more information about this report visit

View source version on

Business Wire

Last updated on: 12/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.